Pertuzumab for the treatment of breast cancer: a safety review

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Expert Opinion on Drug Safety

• Publication date

  2016-03-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14740338.2016.1167185PMID 26982349
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.

  2018cited by this paper
• Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib

  2017cited by this paper
• Abstract P4-14-13: Pertuzumab (P) use in first-line HER2-positive metastatic breast cancer (mBC) in US community oncology practices: Treatment patterns and outcomes

  2016cited by this paper
• The co-administration of pertuzumab (P) and trastuzumab (T) as a single infusion, followed by vinorelbine (V), in first-line (1L) treatment of HER2-positive locally advanced or metastatic breast cancer (MBC) patients (pts): VELVET study interim analysis.

  2015influential reference
• Skin and subcutaneous tissue disorders (SSTDs) in patients (pts) with HER2-positive metastatic breast cancer (MBC) in the phase III trial CLEOPATRA of pertuzumab or placebo with trastuzumab and docetaxel.

  2015cited by this paper
• Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

  2015cited by this paper
• Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

  2015cited by this paper
• Skin, nail, and staphylococcal infections associated with the addition of pertuzumab to trastuzumab-based chemotherapy.

  2015cited by this paper
• Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic

  2014cited by this paper
• Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors.

  2014cited by this paper
• 361PDINTERIM SAFETY AND EFFICACY OF PERTUZUMAB, TRASTUZUMAB AND VINORELBINE FOR FIRST-LINE (1L) TREATMENT OF PATIENTS (PTS) WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (MBC).

  2014cited by this paper
• Risk of severe diarrhea with dual anti-HER2 therapies: a meta-analysis

  2014cited by this paper
• Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA.

  2014cited by this paper
• Targeted therapy-induced diarrhea: A review of the literature.

  2014cited by this paper
• Guidance on the management of diarrhoea during cancer chemotherapy.

  2014cited by this paper
• Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer.

  2013cited by this paper
• Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).

  2013influential reference
• Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.

  2013cited by this paper
• Cardiac toxicity in breast cancer patients treated with dual HER2 blockade

  2013cited by this paper
• Absence of pharmacokinetic drug–drug interaction of pertuzumab with trastuzumab and docetaxel

  2013cited by this paper
• Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)

  2013cited by this paper
• Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

  2012influential reference
• Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.

  2012cited by this paper
• Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis

  2012influential reference
• Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

  2012cited by this paper
• Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.

  2012cited by this paper
• Trastuzumab emtansine for HER2-positive advanced breast cancer.

  2012cited by this paper
• Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication

  2011cited by this paper
• The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity.

  2010cited by this paper
• Poster abstracts

  2010cited by this paper
• Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.

  2010influential reference
• Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.

  2010cited by this paper
• In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma

  2009cited by this paper
• Phase I and Pharmacokinetic Study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese Patients with Solid Tumors

  2009cited by this paper
• PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

  2009cited by this paper
• Novel anticancer targets: revisiting ERBB2 and discovering ERBB3

  2009cited by this paper
• Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

  2008cited by this paper
• A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours

  2007influential reference
• A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer.

  2006cited by this paper
• Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.

  2005cited by this paper
• Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex.

  2004cited by this paper
• An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors.

  2003cited by this paper
• Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.

  2002cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper

• Cardiovascular Health Considerations for Primary Care Physicians Treating Breast Cancer Survivors.

  2024cites this paper
• Pertuzumab Charge Variant Analysis and Complementarity-Determining Region Stability Assessment to Deamidation

  2023cites this paper
• Ebselen oxide and derivatives are new allosteric HER2 inhibitors for HER2‐positive cancers

  2023cites this paper
• A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)

  2023cites this paper
• Rare ocular toxicity induced by pertuzumab/QL1209 in healthy chinese subjects: case reports and whole-exome sequencing analysis

  2022cites this paper
• Cardiotoxicity among Patients Using Pertuzumab, Trastuzumab and Taxane with HER2-Positive Early-Stage Breast Cancer: A Single-Centre Experience

  2021cites this paper
• Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer

  2021cites this paper
• Nanomedicine: a promising avenue for the development of effective therapy for breast cancer.

  2020cites this paper
• Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial.

  2020cites this paper
• Pathological outcomes of HER2‐positive non‐metastatic breast cancer patients treated with neoadjuvant dual anti‐HER2 therapy and taxane: An Australian experience

  2020cites this paper
• TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.

  2019cites this paper
• Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine

  2018cites this paper
• Monoclonal antibody‐based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER

  2018cites this paper
• Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia

  2018cites this paper
• Trastuzumab induces PUMA‐dependent apoptosis and inhibits tumor growth in gastric cancer

  2018cites this paper
• Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer

  2017cites this paper
• Paeoniflorin influences breast cancer cell proliferation and invasion via inhibition of the Notch‑1 signaling pathway.

  2017cites this paper
• Practical aspects of pertuzumab treatment in patients with breast cancer — management of the most common adverse events

  2017cites this paper
• Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib

  2017cites this paper
• Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.

  2016cites this paper